Substance / Medication

Cefmetazole sodium

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Prevention of renal stone disease recurrence. A systematic review of contemporary pharmaceutical options.
Sfoungaristos Stavros, Gofrit Ofer N, Yutkin Vladimir et al. · Expert Opin Pharmacother · 2015
PMID: 25881654Meta-Analysis
Strategy to control catheter encrustation with citrated drinks: a randomized crossover study.
Khan Azhar, Housami Fadi, Melotti Roberto et al. · J Urol · 2010
PMID: 20171661RCT
Severe hypoprothrombinemia caused by cefmetazole sodium in a patient undergoing hemodialysis: A case report.
Oka Yoshinari, Matsuda Hiroaki, Miyazaki Masashi · Ther Apher Dial · 2022
PMID: 35293121Case Report
Pathogenesis of Proteus mirabilis in Catheter-Associated Urinary Tract Infections.
Yuan Fei, Huang Ziye, Yang Tongxin et al. · Urol Int · 2021
PMID: 33691318Review
Bacterial biofilm formation on indwelling urethral catheters.
Pelling H, Nzakizwanayo J, Milo S et al. · Lett Appl Microbiol · 2019
PMID: 30811615Review
Pathogenesis ofInfection.
Armbruster Chelsie E, Mobley Harry L T, Pearson Melanie M · EcoSal Plus · 2018
PMID: 29424333ReviewFull text (PMC)
From Catheter to Kidney Stone: The Uropathogenic Lifestyle of Proteus mirabilis.
Norsworthy Allison N, Pearson Melanie M · Trends Microbiol · 2017
PMID: 28017513ReviewFull text (PMC)
Cefmetazole sodium as an allosteric effector that regulates the oxygen supply efficiency of adult hemoglobin.
Shu Peilin, You Guoxing, Li Weidan et al. · J Biomol Struct Dyn · 2024
PMID: 37555593Other
The synergistic Reduning and cefmetazole sodium treatment of severe pneumonia is mediated by the AhR-Src-STAT3 pathway.
Luo Shanjun, Gan Lianfang, Liu Shengxing et al. · J Thorac Dis · 2022
PMID: 35280469OtherFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cefmetazole sodium (substance)
SNOMED CT
370344004
UMLS CUI
C0700470

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.